

The ABCs of CDK 4/6 Inhibitors

Who, When, and Why in
HR-Positive/HER2-Negative MBC ^{CME}

SATURDAY, 28 SEPTEMBER 2019 | 13:00 – 14:30

VENUE: FIRA GRAN VIA, BARCELONA, SPAIN | ROOM: ALICANTE AUDITORIUM, HALL 3

Medscape **LIVE!**

MODERATOR

Nadia Harbeck, MD, PhD

Head of Breast Center
Department of Obstetrics
and Gynecology
University of Munich (LMU)
Munich, Germany

PANELISTS

Valentina Guarneri, MD, PhD

Associate Professor
University of Padova
Istituto Oncologico Veneto IRCCS
Padova, Italy

Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center
for Women's Cancers
Director of Clinical Trials
Breast Oncology
Dana-Farber Cancer Center
Boston, Massachusetts
United States

*This activity is certified for AMA PRA
Category 1 Credit(s)[™]*

AGENDA

13:00

Introduction

Nadia Harbeck, MD, PhD

13:05

Case Presentation:

Consideration of Initial Combination Therapy With CDK 4/6 Inhibitors

Sara Tolaney, MD, MPH

13:10

Clinical Efficacy and Safety Data of Upfront Combination Therapy Used in HR-Positive/HER2- Negative MBC

Panel Discussion

13:35

Case Continuation: Addition of CDK4/6 Inhibitor Therapy Upon Initial Endocrine Therapy Progression

Nadia Harbeck, MD, PhD

13:40

Clinical Efficacy and Safety Data of CDK 4/6 Inhibitor Therapy After Progression on Initial Endocrine Therapy in HR-Positive/HER2- Negative MBC

Panel Discussion

14:05

Case Follow-Up:

Management of CDK 4/6 Inhibitor Therapy Toxicities

Valentina Guarneri, MD, PhD

14:10

Differentiation of Dosing Administration, Monitoring, and Mitigation of AEs for CDK 4/6 Inhibitor Therapy

Panel Discussion

14:25

Concluding Remarks and Audience Q&A

Nadia Harbeck, MD, PhD

14:30

Adjourn



Lunch offered by Medscape